SI-BONE Stock

SI-BONE Forward P/E

The Forward P/E Ratio of SI-BONE (SIBN) as of Aug 21, 2026 is -29.83. In the previous year, Forward P/E Ratio was -18.24 — a change of 63.49% (lower).

Forward P/E

-29.83

YoY

63.49%

Last updated:

Forward P/E Ratio of SI-BONE is 2026 -29.83 . Forward P/E Ratio of SI-BONE was 2025 -18.24 . It decreases by 63.49% lower compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

SI-BONE Stock analysis

What does SI-BONE do? SI-BONE Inc. is an innovative medical technology company based in Santa Clara, California. It was founded in 2008 by a group of orthopedic surgeons, engineers, and entrepreneurs who aimed to improve the treatment of lower back pain. The company is now globally recognized and specializes in the development and marketing of implants for the treatment of pain and discomfort in the pelvic and back areas. SI-BONE focuses on the treatment of pain and discomfort in the pelvic and back areas, offering a range of products for this purpose. The company's main focus is on the development of innovative implants that can be used minimally invasively, with the goal of providing patients with quick recovery and improved quality of life. The flagship product of SI-BONE is the iFuse implant. This implant is used in patients with chronic lower back pain caused by instability of the spine or pelvis. The iFuse implant stabilizes the pelvis and thereby reduces the pain originating from the unstable joint region. The iFuse implant has been FDA approved and is now available in over 40 countries worldwide. In addition to the iFuse implant, SI-BONE also offers a variety of other products tailored to the needs of physicians and patients. These include implantable instruments and consumables such as bone screws or arthroscopy needles. SI-BONE is a publicly traded company listed on NASDAQ under the ticker symbol "SIBN." The company's business model is based on providing innovative products to physicians and hospitals that optimize the treatment of back pain. To achieve this, SI-BONE works closely with leading industry professionals to enable optimal treatment of back pain. SI-BONE has established itself as a strong, innovative company specializing in minimally invasive implants in the field of pain therapy. Through close collaboration with physicians and specialists and investment in research and development of cutting-edge technologies, SI-BONE aims to continue growing and achieve a leading position in the field of pain therapy. SI-BONE is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SI-BONE stock

Forward P/E Ratio of SI-BONE is -29.83 in 2026.

Forward P/E Ratio of SI-BONE changed from -18.24 to -29.83, representing a 63.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio SI-BONE since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's SI-BONE with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — SI-BONE

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — SI-BONE